Generic placeholder image

Current Women`s Health Reviews

Author(s): Hayam Fathy Mohammad, Nashwa El-Khazragy*, S. Hassan, Fatma Abukra, Rehab M. Abdelrahman, Amr Ahmed Mahmoud Riad and Mohamed A. Abdelhafeez

DOI: 10.2174/1573404817666210310162554

DownloadDownload PDF Flyer Cite As
HE4 is a Beneficial Biomarker in Endometrial Adenocarcinoma

Article ID: e031121192201 Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Endometrial carcinoma ranks second among the most common gynecological malignancy in developing countries. Biomarkers are needed to aid in screening the disease and predicting the clinical as well as the therapeutic outcome. Human Epididymis Protein 4 (HE4) is a protein that was first isolated from human epididymis cells. HE4 levels are elevated in various types of cancers, such as ovarian and gastric cancer.

Objectives: We aim to assess the association of serum and tissue, HE4, and endometrial adenocarcinoma in 77 Egyptian patients divided into two groups: 37 patients in the endometrial cancer group and 40 patients in the control group.

Results: We found that HE4 levels were significantly increased in both serum and tissue of the endometrial cancer group compared to the negative control group. Moreover, higher expression levels were significantly associated with high-grade tumors. HE4 showed excellent diagnostic and prognostic value with a sensitivity and specificity of over 90 percent.

Conclusion: We conclude that both serum and tissue expression of HE4 are sensitive, specific diagnostic and prognostic biomarkers in endometrial adenocarcinoma. In addition, they can predict extra- uterine involvement and staging of the disease.

Keywords: Human epidydmus 4, endometrial carcinoma, prognosis, biomarkers, PTEN, KRAS.

Graphical Abstract

[1]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787]
[2]
Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009; (2): CD000402-.
[http://dx.doi.org/10.1002/14651858.CD000402.pub3] [PMID: 19370558]
[3]
Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338(8762): 274-7.
[http://dx.doi.org/10.1016/0140-6736(91)90417-N] [PMID: 1677110]
[4]
Iqbal J, Ginsburg OM, Wijeratne TD, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treat Rev 2012; 38(4): 318-28.
[http://dx.doi.org/10.1016/j.ctrv.2011.06.009] [PMID: 21775065]
[5]
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body- mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371(9612): 569-78.
[http://dx.doi.org/10.1016/S0140-6736(08)60269-X] [PMID: 18280327]
[6]
Karageorgi S, Hankinson SE, Kraft P, De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976-2004. Int J Cancer 2010; 126(1): 208-16.
[http://dx.doi.org/10.1002/ijc.24672] [PMID: 19551854]
[7]
McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. Am J Epidemiol 1996; 143(12): 1195-202.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a008707] [PMID: 8651218]
[8]
Furberg A-S, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003; 104(6): 669-76.
[http://dx.doi.org/10.1002/ijc.10974] [PMID: 12640672]
[9]
Lucenteforte E, Talamini R, Montella M, et al. Family history of cancer and the risk of endometrial cancer. Eur J Cancer Prev 2009; 18(2): 95-9.
[http://dx.doi.org/10.1097/CEJ.0b013e328305a0c9] [PMID: 19337055]
[10]
Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000; 60(13): 3605-11.
[PMID: 10910075]
[11]
Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88(4): 814-24.
[http://dx.doi.org/10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U] [PMID: 10679651]
[12]
Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58(16): 3526-8.
[PMID: 9721853]
[13]
Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13(3): 295-308.
[http://dx.doi.org/10.1038/modpathol.3880051] [PMID: 10757340]
[14]
Jolly S, Vargas CE, Kumar T, et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol 2006; 103(1): 87-93.
[http://dx.doi.org/10.1016/j.ygyno.2006.01.038] [PMID: 16545441]
[15]
Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10(1): 31-46.
[http://dx.doi.org/10.1002/ssu.2980100107] [PMID: 8115784]
[16]
Silverman MB, Roche PC, Kho RM, Keeney GL, Li H, Podratz KC. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol 2000; 77(1): 1-7.
[http://dx.doi.org/10.1006/gyno.2000.5751] [PMID: 10739683]
[17]
Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009; 106(12): 4834-9.
[http://dx.doi.org/10.1073/pnas.0806514106] [PMID: 19261849]
[18]
Werner HMJ, Salvesen HB. Current status of molecular biomarkers in endometrial cancer. Curr Oncol Rep 2014; 16(9): 403-3.
[http://dx.doi.org/10.1007/s11912-014-0403-3] [PMID: 25064587]
[19]
Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7(2): 167-74.
[http://dx.doi.org/10.1016/S1470-2045(06)70579-4] [PMID: 16455481]
[20]
Guo YD, Wang JH, Lu H, et al. The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer. Tumour Biol 2015; 36(4): 2457-64.
[http://dx.doi.org/10.1007/s13277-014-2858-0] [PMID: 25432133]
[21]
Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65(6): 2162-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-3924] [PMID: 15781627]
[22]
Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008; 110(2): 196-201.
[http://dx.doi.org/10.1016/j.ygyno.2008.04.002] [PMID: 18495222]
[23]
Dotters DJ. Preoperative CA 125 in endometrial cancer: Is it useful? Am J Obstet Gynecol 2000; 182(6): 1328-34.
[http://dx.doi.org/10.1067/mob.2000.106251] [PMID: 10871446]
[24]
Hsieh C-H, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 2002; 86(1): 28-33.
[http://dx.doi.org/10.1006/gyno.2002.6664] [PMID: 12079296]
[25]
Modarres-Gilani M, Vaezi M, Shariat M, Zamani N, Nourizadeh R. The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma. Cancer Biomark 2017; 20(2): 135-41.
[http://dx.doi.org/10.3233/CBM-160529] [PMID: 28800309]
[26]
Chang X, Ye X, Dong L, et al. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer 2011; 21(5): 852-8.
[http://dx.doi.org/10.1097/IGC.0b013e31821a3726] [PMID: 21633297]
[27]
Bie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol 2014; 12: 169-9.
[http://dx.doi.org/10.1186/1477-7819-12-169] [PMID: 24885319]
[28]
Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011; 121(3): 487-91.
[http://dx.doi.org/10.1016/j.ygyno.2011.02.022] [PMID: 21420727]
[29]
Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, et al. Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients. OncoTargets Ther 2017; 10: 3169-75.
[http://dx.doi.org/10.2147/OTT.S136750] [PMID: 28721066]
[30]
Li X, Gao Y, Tan M, et al. Expression of HE4 in Endometrial Cancer and Its Clinical Significance. BioMed Res Int 2015; 2015: 437468.
[http://dx.doi.org/10.1155/2015/437468] [PMID: 26539494]
[31]
Dewan R, Dewan A, Hare S, Bhardwaj M, Mehrotra K. Diagnostic performance of serum human epididymis protein 4 in endometrial carcinoma: A pilot study. J Clin Diagn Res 2017; 11(7): XC01-5.
[http://dx.doi.org/10.7860/JCDR/2017/28926.10285] [PMID: 28893024]